Forodesine
 | |
| Clinical data | |
|---|---|
| Trade names | Mundesine and Fodosine |
| Routes of administration | oral |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C11H14N4O4 |
| Molar mass | 266.26 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Forodesine (INN; also known as Immucillin H; trade names Mundesine and Fodosine) is a transition-state analog inhibitor of purine nucleoside phosphorylase[1] studied for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and for treatment of B-cell acute lymphocytic leukemia (B-ALL).
Forodesine was originally discovered by Vern Schramm's laboratory at the Albert Einstein College of Medicine in New York and Industrial Research Limited in New Zealand.
Forodesine is being developed by BioCryst Pharmaceuticals. As of 2008, it is currently in phase II clinical trials.[2].
In 2006, BioCryst entered into a licensing agreement with Mundipharma International Holdings Limited to develop and commercialize forodesine in markets across Europe, Asia, and Australasia for use in oncology.[3]
In April 2017, forodesine was approved in Japan for the treatment of relapsed/refractory peripheral T-cell lymphoma.[4]
References
- ↑ Kicska GA, Long L, Hörig H, et al. (April 2001). "Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes". Proc. Natl. Acad. Sci. U.S.A. 98 (8): 4593–8. Bibcode:2001PNAS...98.4593K. PMC 31879
. PMID 11287638. doi:10.1073/pnas.071050798. - ↑ "Complete list of clinical trials for forodesine (BCX-1777) (ClinicalTrials.gov)". Retrieved 2008-07-22.
- ↑ "Biocryst Initiates Pivotal Fodosine Phase IIb Clinical Trial In Patients With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma" (Press release). January 16, 2007.
- ↑ "BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan" (Press release). April 3, 2017.
See also
External links
- "From cell biology to therapy: forodesine". Hematology Meeting Reports. 2 (5): 106–111. 2008.
- Gore, L; Stelljes, M; Quinones, R (2007). "Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: Facilitation of graft-versus-leukemia effect?". Seminars in Oncology. 34 (6 Suppl 5): S35–9. PMID 18086346. doi:10.1053/j.seminoncol.2007.11.005.
- 18 December 2006 Fodosine orphan designation by the European Commission for acute lymphoblastic leukaemia.
- BioCryst Pharmaceuticals, Inc. have entered into an exclusive license agreement with Mundipharma for develop and commercialize BioCryst’s lead compound, Forodesine.
- Birmingham, Alabama – February 2, 2006 Mundipharma will obtain rights in markets across Europe, Asia and Australasia to Forodesine™ in the field of oncology in exchange for a $10 million up-front payment. Furthermore, Mundipharma will commit up to an additional $15 million to assist in the evaluation of Forodesine’s™ therapeutic safety and efficacy profile. BioCryst may also receive future event payments totalling $155 million in addition to royalties on product sales of Forodesine™ by Mundipharma.
- News BioCryst provides Fodosine update March 27, 2007. "Voluntarily Placed on Hold by BioCryst (...) we don't think the final response rate will be as high as 18%".
- The European Commission granted a marketing authorisation valid throughout the European Union for Atriance on 22 August 2007 for acute lymphoblastic leukaemia. What benefit has Atriance shown during the studies? Atriance was shown to be effective in a proportion of the patients in both studies. In the first study, among the 39 children and young adults who se cancer had not responded to two or more previous treatments, five (13%) had a complete response to treatment after a month, with no evidence of disease and normal blood counts. In the second study, among the 28 adults and adolescents with cancer that had not responded to two or more previous tre atments, five (18%) had a complete response to treatment. In both studies, more patients had a partial response to Atriance treatment, with blood counts returning towards normal levels.
- Lino Berton collects all the information on Forodesine in www.linoberton.com site, putting them in a row. In 2014 he published the book Qualcosa che non muore where he tells his incredible experience in the closed trial early in 2007.
- Il Giornale.it (in Italian). "Come si boicotta un farmaco che funziona". Dated 08-01-2016.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.